Your browser doesn't support javascript.
loading
Acceptability of a Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-033 Study).
Bauermeister, José A; Tingler, Ryan C; Johnson, Sherri; Macagna, Nicole; Lucas, Jonathan; Dominguez-Islas, Clara; Szydlo, Daniel; Ngo, Julie; Jacobson, Cindy E; Kramzer, Lindsay; Singh, Devika; Dezzutti, Charlene S; Kunjara Na Ayudhya, Ratiya Pamela; Piper, Jeanna; Devlin, Bríd; Hendrix, Craig W; Ho, Ken.
Afiliación
  • Bauermeister JA; University of Pennsylvania, Philadelphia, Pennsylvania.
  • Tingler RC; University of Pennsylvania, Philadelphia, Pennsylvania.
  • Johnson S; FHI 360, Durham, North Carolina.
  • Macagna N; FHI 360, Durham, North Carolina.
  • Lucas J; FHI 360, Durham, North Carolina.
  • Dominguez-Islas C; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, Washington.
  • Szydlo D; Statistical Center for HIV/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Ngo J; Statistical Center for HIV/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Jacobson CE; University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Kramzer L; University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Singh D; University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Dezzutti CS; University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Kunjara Na Ayudhya RP; Microbicide Trials Network, Pittsburgh, Pennsylvania.
  • Piper J; University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania.
  • Devlin B; Division of AIDS/NIAID/NIH, Bethesda, Maryland.
  • Hendrix CW; International Partnership for Microbicides, Silver Spring, Maryland.
  • Ho K; Microbicide Trials Network, Pittsburgh, Pennsylvania.
AIDS Educ Prev ; 33(5): 361-376, 2021 10.
Article en En | MEDLINE | ID: mdl-34596427
ABSTRACT
We triangulated quantitative and qualitative assessments to evaluate participants' acceptability of 0.05% dapivirine rectal microbicide (RM) gel administered via two separate modalities (a rectal applicator and an artificial phallus for use as a coital simulation device) as part of a Phase I trial (N = 14) among men who have sex with men (MSM) randomized using a 11 ratio. Overall, participants reported favorable acceptability of the gel (n = 11; 78.6%), the same or more at the end of the study compared to when they started the study. Additionally, when discussing their preferred administration modality, they noted that both methods had positive qualities but also potential areas of improvement. Our findings underscore the need to create multiple delivery methods for a future microbicide gel (i.e., with and without the need for an applicator) and highlight the importance of offering MSM choices in how biomedical HIV prevention strategies are delivered.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Minorías Sexuales y de Género Tipo de estudio: Clinical_trials / Qualitative_research Límite: Adult / Humans / Male Idioma: En Revista: AIDS Educ Prev Asunto de la revista: EDUCACAO / SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Minorías Sexuales y de Género Tipo de estudio: Clinical_trials / Qualitative_research Límite: Adult / Humans / Male Idioma: En Revista: AIDS Educ Prev Asunto de la revista: EDUCACAO / SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2021 Tipo del documento: Article